J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blumer, J. L.
Right arrow Articles by Ouellet, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumer, J. L.
Right arrow Articles by Ouellet, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS

Pharmacokinetics of Quinapril in Children: Assessment during Substitution for Chronic Angiotensin-Converting Enzyme Inhibitor Treatment

Jeffrey L. Blumer, PhD, MD, Stephen R. Daniels, MD, PhD, William J. Dreyer, MD, Donald Batisky, MD, Philip D. Walson, MD, Doina Roman, MD and Daniele Ouellet, PhD

From the University Hospitals of Cleveland, Cleveland, Ohio (Dr. Blumer); Children's Hospital Medical Center, Cincinnati, Ohio (Dr. Daniels); Baylor College of Medicine, Houston, Texas (Dr. Dreyer); Children's Hospital Research Foundation, Columbus, Ohio (Dr. Batisky, Dr. Walson); and Pfizer Global Research & Development, Ann Arbor, Michigan (Dr. Roman, Dr. Ouellet)

Quinapril pharmacokinetics were studied in infants and children using a novel study design that allowed substitution of quinapril for one dose of the current chronic angiotensin-converting enzyme (ACE) inhibitor treatment. A total of 24 patients ranging in age from 2.5 to 82 months who were receiving an ACE inhibitor held their usual treatment on the study day and received a 0.2-mg/kg dose of quinapril syrup. Blood samples were collected through 24 hours postdose, and plasma was analyzed for quinapril and its active metabolite, quinaprilat. Quinapril was rapidly converted to quinaprilat. Quinaprilat concentrations generally peaked 1 to 2 hours postdose and declined with a mean half-life of 2.30 hours. Dosing on a mg/kg basis resulted in quinaprilat AUC and Cmax values that were generally comparable across the age range of patients in this study. The overall mean AUC0-{infty} was 993 ng•h/mL (range: 533-1523), and mean Cmax was 260 ng/mL (range: 70.0-445.5). Quinaprilat CL/F correlated well with body size (body surface area or weight) and creatinine clearance (mL/min). Pharmacokinetic results after a 0.2-mg/kg dose in infants and children are comparable to those observed following a 10-mg dose in adults.

Address for reprints: Daniele Ouellet, PhD, Pfizer Global Research and Development (Ann Arbor), 2800 Plymouth Road, Ann Arbor, MI 48105.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 HypertensionHome page
D. K. Benjamin Jr, P. B. Smith, P. Jadhav, J. V. Gobburu, M. D. Murphy, V. Hasselblad, C. Baker-Smith, R. M. Califf, and J. S. Li
Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range
Hypertension, April 1, 2008; 51(4): 834 - 840.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology